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The role of SERPIND1 gene in the development of breast cancer is completely unknown. The aim of the present study 
was to assess the expression of SERPIND1 in patients suffering from breast malignancies. Tumoural specimens and non-
tumoural adjacent tissues were collected from 31 patients who were pathologically confirmed for breast cancer. 
Furthermore, 43 fasting venous blood samples were collected from the breast cancer patients as well as from the healthy 
volunteers as control group. The SERPIND1 mRNA expression levels were assessed using the q-RT PCR while the plasma 
levels of SERPIND1 protein were detected using ELISA. The SERPIND1 relative expression levels were compared with the 
clinicopathological factors. The expression of the SERPIND1 was significantly higher at both mRNA and protein levels in 
breast cancer patients compared to the control groups. Moreover, the relative expression of the SERPIND1 showed a 
significant positive correlation with cancer grade, stage and presence of metastasis (P< 0.05). The findings suggest that the 
SERPIND1 may be a metastasis-enhancer factor in breast cancer and a strong predictive marker for distinguishing patients 
with poor prognosis.  
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Breast cancer is the most common malignancy found 
in women. The disease is highly prevalent throughout 
the world
1-3
. Being the second most common cancer 
(after skin cancer), breast cancer encompasses 26% of 
all cancer cases in females. It is also the fifth most 
common cause of death due to cancer
2-5
. Although 
preventive measures or early detection programmes 
can reduce the mortality risk of breast cancer, no 
success is achieved in most of the cases. This is 
especially more pronounced in developing countries 
where the disease is mostly diagnosed in late stages
6
. 
Nowadays, mammography imaging modality is used 
as a gold standard method for diagnosis and screening 
of breast cancer. However, this method has limitations 
due to the use of ionizing radiation and low detection 
sensitivity (false positive rate of 8%-10%) and the 
fact that it is painful for the patients
7-9
. Cancer antigen 
(CA) 15-3 and carcinoembryonic antigen (CEA) are 
currently the most common tumour markers which are 
routinely used. Notably, CA15-3 has the highest 
sensitivity and specificity among these tumour 
markers
8-10
. However, the sensitivity of these markers 
in the detection of early-stage breast cancer is low; 
thus, more extensive studies are needed to find new, 




SERPIND1, also known as heparin cofactor II 
(HCII), belongs to the serpin gene superfamily. It is a 
plasma glycoprotein and protease inhibitor which acts 
as a thrombin inhibitor while interacting with 
heparin, dermatan sulfate, and other endogenous 
glycosaminoglycans
10,11
. It is cytogenetically located 
on chromosome 22 (22q11. 21). SERPIND1 contains 
5 exons with a genomic size of 13608 bp. The highest 
expression of this gene has been detected in the liver 
tissue
12
. Over the past 30 years, SERPIND1 has been 
periodically studied as a protease inhibitor. Recent 
assessments showed that the SERPIND1 protein 
presents in the serum of patients with B-Cell acute 
lymphoblastic leukemia (B-ALL) can be used as a 
selected biomarker for early detection of B-ALL
13
. 
SERPIND1 was overexpressed in the tumoural tissue 








from ovarian epithelial carcinoma
14
. The reports 
suggest that higher expression of SERPIND1 in the 
tissues of ovarian carcinoma is associated with poor 
prognosis in the patients. Moreover, it seems that 
SERPIND1 increases the ability of invasion and 
metastasis of lung cancerous cells
16
. Also, it was 
reported that SERPIND1 plays a role in the metastasis 
of breast cancer to the brain
17
. In general, it seems that 
the expression of SERPIND1 has a Stimulating effect 
on tumour growth and it exacerbates cancer invasion. 
Anyway, the biological effect of SERPIND1 protein 
activity on different kinds of cancer is still largely 
unknown; particularly, it has never been studied in 
breast cancer.  
Thus, for the first time, we assessed the relative 
expression of SERPIND1 at mRNA and protein levels 
in the tissue and plasma of breast cancer patients, as 
well as evaluating the correlation between the relative 
expression of SERPIND1 and the clinicopathological 
features. The results may help further studies aimed at 
a better understanding of the molecular mechanisms 
of the SERPIND1 involvement in tumourigenesis, 
progression, and metastasis of breast cancer.  
The results can also pave the way for the development 
of new treatments for breast cancer patients.  
 
Patients and Methods 
 
Specimen preparation 
Thirty-one Breast cancer tissues (BCT) and thirty-
one non-tumoural adjacent tissues (NTAT) were 
collected by the Tumour Bank of the Cancer Institute 
(Imam Khomeini Hospital Complex, Tehran, Iran) 
regarding the rules of ethics in experimental and 
medical studies. The samples were taken from 
patients diagnosed with breast cancer and undergone 
surgery at Imam Khomeini Hospital Complex from 
2008 to 2018. Tissue specimens were kept in 
sterilized cryo tube rack in a liquid nitrogen tank at 
−180C since surgery until further analysis. The 
patients were in the age range of 32 to 81 years old 
with the mean age ± S. D of 54 ± 12. None of the 
patients had undergone radiotherapy, chemotherapy 
or any kinds of medication before the surgery.  
The specimens were fixed on slides and were  
stained using the hematoxylin & eosin (H&E)  
staining technique, and then were examined by a 
pathologist and confirmed as breast cancer. The 
clinicopathological factors including age, tumour size, 
types of metastasis, and the status of hormon 
receptors (HR), human epidermal growth factor 
receptor 2 (HER2), and p53 mutation were 
determined using the clinical and histopathological 
information available from the history of patients. 
Tumour stages were determined using the TNM 
Classification of Malignant Tumours of the Union for 





tumour grade was determined by the pathologists 







Plasma Sample Preparation 
Forty-three fasting venous blood samples were 
obtained from the patients who were referred to the 
Imam Khomeini Hospital Complex from 2008 to 
2018 before surgery and any treatment. Patients were 
confirmed as breast cancer based on the results of the 
specific pathology tests, imaging, or biopsy before the 
initiation of any treatment modalities (patients aged 
from 31 to 81 years old with the mean age± S.D of 
53. 67 ±12. 29. Also, venous blood samples were 
collected from forty-three healthy volunteers as the 
control group. The control group had no history of 
malignant diseases. They had not received any blood 
products within the last 3 years, and they were not in 
any inflammatory conditions at the time of sampling 
(individuals aged from 33 to 85 years old with the 
mean age± S.D of 20.50 ±14. 65. The samples were 
collected in EDTA-prepared tubes and immediately 
were centrifuged at 2000 × g for 10 min so that 
plasma was isolated, then they were kept in EP tubes 
(without enzymes) at −80C since preparing until  
the analysis.  
 
Tissue Homogenate Preparation 
To prepare tissue homogenates, 100 mg of tissue 
slice was ground into fine powder using liquid 
nitrogen. Then 100 µL of phenylmethylsulfonyl 
fluoride (PMSF), the protease and phosphatase 
inhibitor, were added based on the protocol, followed 
by adding 1 mL of lysis buffer (contained 50 mM 
Tris-HCl pH:7. 4, 150 mM NaCl, 1mM EDTA, 0.1% 
SDS, 1% Triton X-100, 1% Sodium deoxycholate). 
Samples were immediately centrifuged at 10000 × g 
for 5 min. The supernatant was carefully collected and 
kept in −180C since preparing till the further 
analysis.  
 
Total RNA Extraction  
In the present study, we used the same amounts of 
tissue for RNA extraction to perform the 
normalization process with equal cell numbers.  
RNA extraction was performed using the GTC 
method (guanidinium thiocyanate-phenol-chloroform 






 reagent (Invitrogen, Carlsbad, 
CA, USA, cat No. 15596026). This technique is an 
optimum mechanism for the single-step isolation of 
RNA developed by Chomcynski and Sacchi in 1987
20
. 
The process was as following: after homogenizing the 
samples using liquid nitrogen, 1 mL of TRIzol
TM
 
reagent was added to 100 mg of the homogenized 
tissue. The mixture was centrifuged and then 0.2 mL 
of chloroform was added. The RNA was precipitated 
from the upper phase using 0.5 mL of isopropanol. 
Electrophoresis (4% agarose gel) was used to  
control the quality of the extracted RNA and the 
spectrophotometry was performed using the Nano 
Drop® ND-1000 UV-Vis Spectrophotometerto assess 
the purity and quantity of the extracted RNA.  
The Optical Density ratios of 1. 8-2 and 2-2. 2 were 
considered as the pure RNA at 260 nM vs 280 nM and 
230 nM vs 260 nM, respectively.  
 
cDNA Synthesis and Real-time PCR 
The extracted RNA was converted to cDNA 
following the protocol of the kit (HelixCript
TM 
Thermo Reverse Transcriptase, Nanoahelix, Yuseong-
gu, South Korea, cat No. PT10K). All the steps of 
reverse transcription and PCR for the target and 
control groups were performed with the same 
accuracy, volume and in the same conditions of 
cDNA synthesis. The template RNA was introduced 
into the reverse transcription system with the same 
concentration of 1000 ng for all samples. PCR was 
performed using AMPLIQON Master Mix (Denmark, 
Cat No. A190303) based on the manufacturer 
instructions to evaluate the quality of the synthesized 
cDNA. Then the product underwent electrophoresis 
with 2% agarose gel and the process was confirmed. 
The synthesized cDNA was immediately stored  
at −20C until the next use. The sequences of  
the primers of housekeeping gene, Beta-actin, and 
SERPIND1 were, respectively as following: 
Forward (Beta-actin): 5GATCAAGATCATTGCTC 
CTCCTG3 
Reverse (Beta-actin): 5CTAGAAGCATTTGCGGT 
GGAC3 
Forward (SERPIND1): 5TGAAGTTGATGGGGAT 
CAGG3 
Reverse (SERPIND1): 5GACAGTGAAGCGGACT 
TGG3 
Real time PCR was performed using the  
RealQ Plus 2× Master Mix Green with low ROX
TM
 
kit (AMPLIQON, Denmark, Cat. No. A324406) and  
a thermal cycler (Exicycler
TM
 96 Real-Time 
Quantitative Thermal Block, BIONEER, Daedeok-gu, 
Republic of Korea). The reaction mixture with a final 
volume of 25 µL included:12.5 µL RealQ Plus  
2× Master Mix Green (1X), 0.5 µL of forward primer 
(10 pmol/μL), 0.5 µL of reverse primer (10 pmol/μL), 
2 µL of cDNA (100 ng/μL) and 9.5 µL Rnase-free 
water. The amplification reaction of the two-step 
Real-time PCR was performed double for each 
sample and the following regimen was used: 
A 10 min cycle at 95°C, the main PCR cycle 
including a 15s at 95C following a 60s at 60C with 
40 repetitions. The device software was used for 
calculation of the Ct (threshold cycle) values for the 
target and reference genes. The final Ct difference of 
0.5 between the two repetitions was considered as 
acceptable and the mean Ct value was used as the 
final Ct. The liver tissue sample was considered as the 
positive control. The Livak method with the following 
formula was used to determine the Relative 




∆∆Ct =(Ct target gene – Ct Reference gene)tumour – 
(Ct target gene – Ct Reference gene)control 
 
Assessment of plasma and tissue levels of SERPIND1 protein 
in both groups of breast cancer patients and normal healthy 
individuals using ELISA 
The SERPIND1protein concentration in the plasma 
samples, homogenates from BCT and NTAT were 
detected using the human HCII ELISA kit (Shanghai 
crystal Day Biotech Co., Ltd, Shanghai, China,  
Cat No: E1377Hu). The measurement steps were 
performed thoroughly according to the instructions of 
the kit manufacturer. The measurable concentration 
was in the range of 0.1-40 ng/mL and the analytical 
sensitivity was 0.051 ng/mL.  
 
Data Statistical Analysis 
Statistical analysis were performed using SPSS 
software (Version 20; SPSS Inc., Chicago, IL, USA) 
and the graphs were drawn using Graphpad Prism8 
(Graphpad Software, La Jolla, California, USA, 
http://www. graphpad. com). The quantitative 
variables were initially evaluated for distribution and 
variance equality using the 1-sample K-S and 
Levene’s test, respectively. The independent T-test 
and Mann-Whitney U Test were used to compare 
between two groups with normal and non-normal 
distribution, respectively. The one-way ANOVA with 
DunnettT3 post hoc test was used to compare between 
more than two groups with normal distribution and 
the Kruskal-Wallis H test was used to compare more 
than 2 groups with non-normal distribution. P< 0.05 




was considered as the significance level and in the 
figures, *, P< 0.05; **, P< 0.01; ***, P< 0.001 and 




Evaluation ofSERPIND1 expression in the tumoural tissues 
and non-tumoural adjacent tissues 
SERPIND1 expression was measured by  
qRT–PCR in 31 BCT and 31NTAT as control group.  
As shown in (Fig. 1A), SERPIND1 mRNA expression 
was significantly higher in BCT compared with 
NTAT (t(60)= 1.89, P= 0.04).  
 
Correlation of the SERPIND1 relative expression with the 
clinicopathological factors of Breast Cancer 
As shown in Table 1, SERPIND1relative expression 
in BCT correlates significantly with the histological 
grade. The relative expression of SERPIND1 in grade 
III Breast Cancer patients was significantly higher 
than patients with grade I (Table 2 & Fig. 1B). 
Besides, there was a significant correlation between 
the relative expression of SERPIND1 and the cancer 
stage (Table 1). Information regarding the correlation 
directions in the different stages is summarized in 
(Table 2), where SERPIND1 relative expression in the 
patients with stage II and stage IV breast cancer were 
significantly higher than the patients with stage I  
(Fig. 1C). Also, we found that the SERPIND1 relative 
expression was significantly correlated with the 
tumour size (Table 1). The analysis showed that the 
SERPIND1 relative expression was significantly 
higher in the tumours bigger than 5 cm compared to 
those smaller than 2 cm (Table 2). The relative 
expression of SERPIND1 had no significant 
correlation with the age of the patients (Table 1).  
Moreover, there was a significant positive 
correlation between the HER2 protein expression,  
the cancer grade (correlation coefficient= −0.574,  
P value= 0), stage (correlation coefficient= −0.628,  
P value= 0), and the presence of metastasis 
(correlation coefficient= −0.418, P value = 0.005). 
The status of p53 mutations was positively correlated 
with the cancer stage (correlation coefficient=0.732,  
P value= 0) and grade (correlation coefficient=0.489, 
P value= 0.001) and the presence of distant metastasis 
(correlation coefficient= −0.608, P value= 0). There 
was also a significant positive correlation between the 
ER and PR phenotypes with the cancer stage 
(correlation coefficient= 0.781, P value= 0) and grade 
(correlation coefficient= 0.632, P value= 0), lymph 
node metastasis (correlation coefficient= 0.602,  
P value= 0), and distant metastasis (correlation 
coefficient= −0.667, P value= 0).  
 
Relationship between the SERPIND1 relative expression in 
breast tumoural tissue and the invasive factors of the cancer  
Table 3 summarizes the relationship between the 
SERPIND1 relative expression in the BCT and the 
cancer invasion factors. According to our results, the 
relative expression of the SERPIND1 was significantly 
higher in the patients suffering from metastatic cancer 
including distant metastasis, lymphatic invasion, lymph 
node invasion, perineural invasion, and vascular 
invasion, compared to the patients with non-metastatic  
 
 
Fig. 1 — (A) Relative expression of SERPIND1 in breast cancer tissue (BCT) (n=31) compared with non-tumoural adjacent tissue 
(NTAT) (n=31). The figure shows the quantitative values of expression in scale 2-∆Ct. As shown, the expression of SERPIND1 mRNA is 
significantly higher in BCT than in NTAT (P< 0.05). The mean difference between two groups (± SEM) was calculated as −0.308  
(± 0.162); (B) Comparison of relative tissue expression of SERPIND1 in three histological grades of breast cancer; (grade I (n=6): well 
differentiation, grade II (n=15): moderate differentiation, grade III (n=9): poor differentiation). As shown, the relative expression of the 
SERPIND1 mRNA in Grade III is significantly higher compared to Grade I (P< 0.05); and (C) Relative expression quantity of SERPIND1 
in association with four stages of breast cancer. The relative expression of SERPIND1 in stage I (n=6) has significantly decreased 
compared to stage II (n=11) and stage IV (n=11) (for both P< 0.05). 





Table 1 — Correlation between relative expression of SERPIND1 in breast cancer tissue and clinicopathological features. 
   Relative expression of SERPIND1  






Mean± Std.  
Deviation 






































































Table 2 — Comparison of SERPIND1 relative expression in different grades and stages of breast cancer . 
 
Histology grade (A) 
 
Histology grade (B) 
Relative expression of SERPIND1 
Mean Differences(A-B) Std. Error P value 








Grade II Grade III −52.21 23. 18 5.13 
Stage (A) Stage (B)    




















Stage III Stage IV −27.73 37.26 5.95 
Tumour size(A) Tumour size(B)    








2-5 cm >5 cm −34.56 21.94 5.33 
 
Table 3 — Correlation between relative expression of SERPIND1 in breast cancer tissue with metastasis, hormone receptor status  
(ER and PR), HER2 protein expression status, and p53 tumour suppressor protein mutation status (Contd.) 
Relative expression of SERPIND1  
P value t Df Mean± Std. Deviation N (31) (%)  









3.188 19. 37 42. 96±54.32 






















Table 3 — Correlation between relative expression of SERPIND1 in breast cancer tissue with metastasis, hormone receptor status  
(ER and PR), HER2 protein expression status, and p53 tumour suppressor protein mutation status 
Relative expression of SERPIND1  
P value t Df Mean± Std. Deviation N (31) (%)  
5.01* 
 


























































Table 4 — Descriptive statistics of SERPIND1 protein concentration in plasma of breast cancer patients and healthy individuals.  
Mean concentration of SERPIND1 protein in plasma is 8.27 ng/mL higher with standard error of 2.28 ng/ml in breast  
cancer patients compared to normal subjects 
  Concentration of SERPIND1 protein in plasma (ng/mL)   
P value Z Mean Rank Std. deviation Median Mean N 










Breast cancer patients 
Healthy individuals 
 
cancer. The SERPIND1 relative expression was also 
increased in patients with necrotic tumours compared 
to patients with non-necrotic tumours; however, the 
difference was not significant.  
 
Relationship between the SERPIND1 relative expression  
and the presence of hormonal receptors, HER2 protein 
expression, and the mutation status of the tumour suppressor 
protein p53  
Table 3 summarizes the relationship between the 
SERPIND1 relative expression in BCT and the 
presence of hormonal receptors, HER2 protein 
expression, and p53 mutation status. There was a 
significant increase in the SERPIND1 relative 
expression in the HR-negative patients compared to 
HR-positive patients. Also, the SERPIND1 relative 
expression was higher in the HER2-positive and p53-
negative (having mutations in p53) patients than the 
HER2-neutral (without HER2 expression) and p53-
positive (without p53 mutation) patients; However, 
the differences were not significant.  
Evaluation of plasma SERPIND1 protein levels in the healthy 
and cancer groups and the relationship between the 
SERPIND1protein levels and the clinicopathological features 
As shown in Table 4, the plasma levels of 
SERPIND1 protein were significantly higher in the 
breast cancer group compared to the control group 
(Fig. 2A). The analysis showed that the expression 
level of SERPIND1protein in plasma had a significant 
correlation with the cancer grade (Table 6). Our 
comparative pair analyses showed significant 
differences in SERPIND1 protein levels between 
grade I and grade III patients (P value= 0.001) and  
also between grade II and grade III (P value= 0.009( 
(Fig. 2B). Also, the SERPIND1 protein expression in 
the plasma of breast cancer patients had a significant 
correlation with the clinical stage of cancer (Table 6). 
Our results found significant differences in the 
SERPIND1 protein expression between stage I and 
stage IV (P value= 0.02) and also between stage II  
and stage IV (P value= 0.005) (Fig. 2C). In addition,  
our results showed that plasma expression of SERPIND1  





Table 5 — Descriptive Statistics of SERPIND1 protein concentration in Plasma of Breast cancer patients in early stage of disease 
compared to healthy individuals. Mean concentration of plasma SERPIND1 protein is 1.13 ng/mL higher with standard  
error of 2.64 in breast cancer patients compared to normal individuals, which was not statistically significant 
  Concentration of SERPIND1 protein in plasma (ng/mL)   
 N Mean Median Std. deviation Mean Rank Z P value 
Breast cancer patients in  














Healthy individuals 43 6.02 2.62 9.52 33.30   
 
Table 6 — Correlation between mean plasma levels of SERPIND1 protein in patients with breast cancer with clinicopathological features 
  Plasma SERPIND1 protein levels (ng/mL)   






















































































Fig. 2 — (A) The expression of SERPIND1 protein in the plasma sample of breast cancer patients (n=43) compared to healthy control 
group (n=43). As shown in the figure, the plasma level of SERPIND1 protein expression in breast cancer group is significantly increased 
compared to the control group (P< 0.01); (B) Comparison of plasma levels of SERPIND1 protein in breast cancer patients at different 
histological grades. The figure shows that plasma expression of SERPIND1 protein in breast cancer patients of grade III (n=13) is 
significantly increased compared to patients in grade I (n=10) and II (n=19) (for both P< 0.01); and (C) The expression of SERPIND1 
protein in plasma of breast cancer patients in four stages. Significant increase in plasma SERPIND1 protein concentration in stage IV 
breast cancer patients (n=12) compared to stage I (n=7) (P< 0.05) and II (n=17) (P< 0.01) 
 
protein in early-stage breast cancer groups (stage I 
and II) was not significantly different  
from healthy controls (Table 5). Finally, no significant 
correlation was found between the mean of 
SERPIND1 protein concentration with the tumour size 
and age of patients (Table 6). 
Relationship between the plasma concentration of SERPIND1 
protein and the invasion factors, the status of ER, PR, and 
HER2, and p53 mutation status  
As shown in Table 7, the results showed that the 
mean of SERPIND1 protein plasma levels was higher 
in the patients with distant metastasis, lymphatic 




invasion, and lymph node invasion compared to the 
healthy individuals. Also, the mean concentration of 
SERPIND1 protein in the plasma from the HR-
negative, HER2-positive, and p53-negative patients 
were significantly higher than the HR-positive, 
HER2-negative, and p53-positive patients.  
 
Measurement of SERPIND1protein concentration in the 
breast tumoural tissue homogenates 
The evaluation of SERPIND1 protein concentration 
in the tissue homogenate samples obtained from the 
BCT and NTAT showed that the mean protein 
concentration in the tumoural homogenate was higher 
than the non-tumoural adjacent tissue, which was 
used as the control. However, the difference was not 
significant (Table 8).  
 
Discussion 
SERPIND1 protein tracing and its role in 
tumourigenesis and progression of a variety of 
cancers including B-Cell acute lymphoblastic 
leukemia
13
, ovarian epithelial cancer
14
 and lung 
cancer
15
 have been studied. According to the results 
of these studies, the overexpression of SERPIND1 
appears to play an important role in tumour growth 
promotion, stimulation, and invasive behaviour 
increase of tumoural cells. However, the relationship 
between the expression of this gene and other cancer 
types including breast cancer has not been 
investigated.  
At the present, clinically early cancer screening 
method based on traditional protein tumor marker of 
serum such as CA and CEA has low sensitivity, low 
accuracy and poor specificity. So new specific tumor 
marker of serum are always needed
16
. In the present 
study, we found that there is a significant increase in 
SERPIND1 expression at mRNA and protein levels in 
the BCT compared to the NTAT and in the plasma 
from the breast cancer patients compared to the 
healthy volunteers, respectively. Moreover, we 
showed that the mean of SERPIND1 protein 
concentration was higher in the BCT than the NTAT 
of the same patients by assessing the SERPIND1 
Table 7 — Correlation of plasma levels of SERPIND1 protein in breast cancer patients with metastasis, hormone receptor status  
(ER and PR), HER2 protein expression status, and p53 protein mutation status 
  Plasma SERPIND1 protein levels (ng/mL)   













































































































Table 8 — Descriptive statistics of SERPIND1 protein concentration in breast cancer tissue homogenate compared to the non-tumoural 
adjacent tissue. Mean concentration of the protein is 0.62 ng/mL higher with standard error of 1.54 in breast cancer tissue in contrast to 
the margin of non-tumourous tissue; The difference is not statistically significant 
 Concentration of SERPIND1 protein in tissue hemogenate (ng/mL)   
 N mean Std. deviation Mean Rank Z P value 
Breast cancer tissue 
non-tumoural adjacent tissue 
31 4.50 7.13 31.69 −0.085 5.9 
31 3.88 4.77 31.33 




protein concentration in tissue homogenates; 
however, the increase was not significant, maybe due 
to the small sample size. According to the study 
analyses, the SERPIND1 expression at both mRNA 
and protein levels in the breast cancer patients showed 
that there is a significant correlation between the 
clinicopathological features including grade, stage, 
and size of the tumour. Consequently, the increase in 
the disease grade leads to an increase in the 
SERPIND1 expression in the tumoural tissue and 
plasma of the patients. The increase was highly 
significant and pronounced in patients with grade III 
breast cancer compared to grade I. Also, our 
assessments showed that the SERPIND1 expression in 
tissue and plasma of the patients increased as the 
disease stage progressed, and the gene had the highest 
expression in stage IV. However, in our study, plasma 
levels of SERPIND1 protein were not able to 
differentiate the breast cancer patients in the early 
stages (stages I and II) from healthy individuals. In 
other words, if SERPIND1 protein is used as a 
screening marker, it will increase the overall number 
of people diagnosed with breast cancer, but may not 
be able to detect the disease in the early stages of 
tumour formation. Moreover, our results suggested 
that larger tumours express the SERPIND1 gene at 
significantly higher levels than the smaller tumours. It 
has been reported that there was a significant 
overexpression of SERPIND1 in epithelial ovarian 
cancer, and the patients with higher SERPIND1 
expression levels in the ovarian cancer tissue had a 
poor prognosis, which was in line with our results. 
Evaluating 113 patients with ovarian epithelial cancer 
showed that there is an increased expression of 
SERPIND1 in stages III and IV compared to stages I 
and II. This finding was consistent with our results as 
well. They also reported that the decrease in the 
tumoural cell differentiation caused an increase in the 
expression level of SERPIND1; however, it was not 
significant. This result was not consistent with the 




We found that the SERPIND1 expressions, at both 
mRNA and protein levels, were significantly higher in 
the breast cancer patients with distant metastasis, 
lymphatic invasion, and lymph node metastasis 
compared to those whose disease was not extended 
(non-metastatic). Incompatible with our results, a 
group found that the patients suffering from ovarian 
epithelial cancer with lymph node metastasis had an 
increasing trend of SERPIND1 expression compared 
to those with no lymph node metastasis; however, 
they did not find this increase as significant
14
. 
Previous studies found that the SERPIND1 expression 
increased the cell mobility in Non-small-cell lung 
carcinoma(NSCLC) and also the cancer invasion and 
metastasis, both in vitro and in vivo
15
, which was 
consistent with the results of our study. The study 
found that Ras-related C3 botulinum toxin substrate 
1(Rac1) and Cell division control protein 42 (Cdc42) 
are the SERPIND1 downstream effectors in a PI3k-
dependent manner, and heparin can inhibit the 
SERPIND1 effects on cell migration, invasion, and 
metastasis. They stated that the anti-metastatic effect 
of heparin was more pronounced on the cancer cells 
with overexpression of SERPIND1
15
. In other words, 
maybe the expression levels of SERPIND1 in the 
tissue and plasma can be used as a predictive factor 
for the glycosaminogly can therapy with agents such 
as heparin. Further clinical trials are needed to 
confirm this hypothesis.  
A study has reported that serpins including 
SERPIND1 have a role in breast cancer metastasis to 
the brain
17
. It was also shown that the overexpression 
of SERPIND1 in the malignant breast tissue  
had a significant association with the metastasis 
development, which was in line with our results. This 
effect may be due to several mechanisms. It has also 
been confirmed that Rac1 and Cdc42 activities in lung 
cancer cells showed an increase following the 
treatment with exogenous SERPIND1 protein, 
suggesting that Rac1 and Cdc42 could be the 
filopodium formation effectors through SERPIND1 
protein and result in an increase in the migration of 
lung cancer cells
15
. This effect may explain the 
metastatic potential of the lung cancer cells with 
SERPIND1 overexpression; because the filopodium 
number is closely correlated with the invasive 
phenotype in cancer cells
21,22
. Extensive studies are 
needed to understand the association of filopodium 
number in breast cancer cells with SERPIND1 
overexpression. Since a pronounced and significant 
increase was found in the expression of the RHO 
proteins of Rac1 and Cdc42 in the BCT compared to 
the NTAT of the same patients
22, 23
,these results can 
provide a general explanation for the involvement of 
RHO GTPases in human carcinogenesis and the 
consequent effect of SERPIND1 overexpression on 
the invasion of breast cancer in the present study. 
Considering all findings, it is possible that the 
SERPIND1 overexpression in BCT had also additive 
effects on the proliferation, invasion and metastatic 




potential of the breast cancer cells in our study by 
altering the regulation of the signaling pathways 
mentioned, increasing the filopodium number and 
RHO protein expression, as well as changing the cell 
cycle. However, these interpretations may provide the 
basis for further studies in this area aimed to clarify 
the possible role of this factor as a metastasis 
enhancer in breast cancer. Moreover, it was found that 
SERPIND1 caused increases in the proliferation, 
migration, invasion, the transition from G1 phase  
into S phase of the cell cycle, and the epithelial-
mesenchymal transition (EMT) in the ovarian cancer 
cells while decreasing the apoptosis of these cells 
through increasing the phosphorylation of PI3K and 
AKT. Also, it was reported that PI3K was possibly a 
downstream effect or of SERPIND1
24-26
. Various 
studies reported that EMT played a key role in the 
initiation of metastasis and increasing the migration 
and invasion capacity of the cancers including breast 
cancer 
27-29
. According to the results of the present 
study, it is also possible that the overexpression of 
SERPIND1 was associated with the PI3K activation 
and EMT increase in breast cancer cells, thereby 
increasing the invasion potential of them. Further 
studies can discover new molecular markers to predict 
disease recurrence and prognosis as well as new 
targets for gene therapy and medication development 
by creating cell lines with SERPIND1 overexpression, 
clarifying the regulatory mechanisms associated  
with this gene, and a better understanding of the 
regulatory mechanisms associated with EMT in  
breast cancer.  
In the present study, all samples had HR-positive 
or HR-negative phenotypes. By gene expression 
analysis, we found that the relative expression of the 
SERPIND1 gene showed significant increases in 
tumoural tissue and plasma of HR-negative breast 
cancer patients compared to HR-positive individuals. 
According to the reports, the increase in the number 
of hormonal receptors in tumoural cells increased the 
response to endocrine therapy while decreasing the 
disease recurrence and mortality rates; besides, 
women with receptor-positive phenotypes had a better 
prognosis including lower tumour proliferation  
rates and histologic evidence of higher tumour 
differentiation
30-32
. Our study was in line with these 
interpretations, showing higher expression levels of 
SERPIND1 were in HR-negative patients. This 
expression had a positive correlation with grade and 
stage of the disease and tumour size, probably 
suggesting a poor prognosis in the ER-negative and 
PR-negative patients with SERPIND1 overexpression. 
Moreover, we showed that the lack of hormonal 
receptors had a positive correlation with the disease 
grade, disease stage, axillary lymph node metastasis, 
and distant clinical metastasis. These findings support 
the results above. In conclusion, it can be said that the 
SERPIND1 overexpression, which correlates with the 
lack of HR expressions in cancer cells, results in 
higher tumour growth and higher spread of it. Further 
studies are necessary on the underlying mechanisms 
through which SERPIND1 leads to increased tumour 
growth and its association with the HR status.  
Our findings showed that the patients with HER2 
expression in cancer cells had significantly higher 
plasma levels of SERPIND1protein than the patients 
who lacked HER2 expression. Overexpression of 
HER2 resulted in an increased response to the stromal 
growth factors and oncogenic transitions. It has also 
been reported that HER2 is associated with 
malignancy development, a significant reduction in 
the survival rate, and poor prognosis of breast 
cancer
33-35
. Also, we found a positive correlation 
between the disease stage and grade with the plasma 
expression of HER2 protein; since the HER2-positive 
breast cancer is more invasive, we should consider 
that the increased levels of SERPIND1protein in  
the plasma of these patients can be an indicator  
of adverse prognosis, more invasive tumour, and 
 a consequent higher likelihood of metastasis in  
breast cancer patients, which can be helpful in  
the targeted treatment of the patients. However,  
more studies are needed to clearly understand  
the relationship between SERPIND1 expression  
and the expression level of the HER2 in breast  
cancer patients.  
Our analysis also indicated that patients with 
mutations in p53 protein had significantly higher 
plasma levels of SERPIND1protein compared to the 
patients without p53 mutations. Various studies have 
reported that p53 mutations possibly were associated 
with more invasive disease, distant metastasis, and 
less total survival rate in breast cancer patients
36
.  
Our study showed that the increase in tumour size  
and cancer stage increases the possibility of p53 
mutations. In agreement with this result, other studies 
reported that mutations in this protein were 
significantly more prevalent in T3 tumours (larger 
than 5 cm)
37
. In the present study, overexpression of 
SERPIND1 was found in breast cancer patients with 
p53 mutations. Since these changes in p53 usually 
occur in the advanced stages of breast cancer, more 




extensive studies are needed to confirm that 
SERPIND1 expression could be associated with  
p53 mutation and the metastatic potential of the 
cancer cells.  
The present study was the first to investigate the 
association between SERPIND1 and breast cancer 
tumourigenesis and the more invasive behaviour of 
breast tumours. It has shed a light on the potential use 
of SERPIND1 protein as a plasma tumour marker or 
targeted therapy. However, further assessments are 
needed to elucidate the underlying mechanisms.  
 
Conclusion 
The evidence provided by the present study 
showed that SERPIND1 might be a novel metastasis-
enhancing factor in breast cancer, a strong predictor 
for identifying the patients with poor prognosis, and a 
marker for disease recurrence estimation. At the same 
time, these results may help the development of new 
agents for breast cancer targeted therapy. Further 
studies on SERPIND1 and its role in the molecular 
processes involved in tumourigenesis, cell growth, 
and metastasis in breast cancer may elucidate the 
underlying mechanisms behind the rise of biologically 
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